TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) Co-administered With a Commercially Available Vaccine in Healthy Female Adolescents
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical cancer, and so HPV vaccination could complement the existing pre-adolescent/adolescent vaccination programs. Therefore, this Phase IIIb study is designed to evaluate the safety and immunogenicity of co-administering a commercially available vaccine with GSK Biologicals' HPV-16/18 L1 AS04 (Cervarix ®) vaccine as compared to the administration of either vaccine alone. This Protocol Posting has been updated in order to comply with the FDA AA, Sept 2007.


Options:
A: Arm Label: Cervarix™ & Twinrix™ Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™, Biological: Twinrix ™ Paediatric | Arm Label: Cervarix™ Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Twinrix™ Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Twinrix ™ Paediatric | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix™ & Twinrix™ Group, Cervarix™ Group | Intervention Type: BIOLOGICAL; Name: Twinrix ™ Paediatric; Assigned to Arm(s): Cervarix™ & Twinrix™ Group, Twinrix™ Group
B: Arm Label: Cervarix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Al(OH)3 | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: DRUG; Name: Placebo Al(OH)3; Assigned to Arm(s): Placebo Group
C: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1 VLP AS04; Assigned to Arm(s): N/A
D: Arm Label: 0,2,6 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,3,9 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,6,12 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,12,24 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Intervention Type: BIOLOGICAL; Name: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): 0,12,24 month vaccination schedule, 0,2,6 month vaccination schedule, 0,3,9 month vaccination schedule, 0,6,12 month vaccination schedule

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
Brief Summary: AMB-320/321-E was designed to provide long-term, controlled monitoring of pulmonary arterial hypertension (PAH) patients treated with ambrisentan (AMB) in order to properly define the adverse event profile associated with this endothelin receptor antagonist (ERA), including the incidence and severity of elevated serum liver function tests (LFTs). In addition, this study continued the efficacy assessments of the previous studies, examined long-term AMB treatment success, and compared long-term survival of subjects treated with AMB to the NIH registry of patients with PAH.


Options:
A: Intervention Type: DRUG; Name: Bosentan administration; Assigned to Arm(s): N/A
B: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Ambrisentan
C: Arm Label: ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): ambrisentan, sugar pill
D: Arm Label: STI571; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: All Patients; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Intervention Type: DRUG; Name: Imatinib mesylate; Assigned to Arm(s): All Patients, STI571 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
Brief Summary: AMB-320/321-E was designed to provide long-term, controlled monitoring of pulmonary arterial hypertension (PAH) patients treated with ambrisentan (AMB) in order to properly define the adverse event profile associated with this endothelin receptor antagonist (ERA), including the incidence and severity of elevated serum liver function tests (LFTs). In addition, this study continued the efficacy assessments of the previous studies, examined long-term AMB treatment success, and compared long-term survival of subjects treated with AMB to the NIH registry of patients with PAH.


Options:
A: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: STI571; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: All Patients; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Intervention Type: DRUG; Name: Imatinib mesylate; Assigned to Arm(s): All Patients, STI571 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
D: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Ambrisentan

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.
Brief Summary: To develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to bisphosphonates.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoporosis Choice Decision Aid | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Osteoporosis Choice Decision Aid; Assigned to Arm(s): Arm 1
B: Arm Label: 1 Patient decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: 1 Patient decision aid, Behavioral: 2 Usual care | Arm Label: 2 Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 Usual care | Intervention Type: BEHAVIORAL; Name: 1 Patient decision aid; Assigned to Arm(s): 1 Patient decision aid | Intervention Type: BEHAVIORAL; Name: 2 Usual care; Assigned to Arm(s): 1 Patient decision aid, 2 Usual care
C: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
D: Arm Label: Patient Decision Aid for an ICD (primary prevention, non-CRT); Type: EXPERIMENTAL; Interventions: Behavioral: Patient Decision Aid for an ICD (primary prevention, non-CRT) | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient Decision Aid for an ICD (primary prevention, non-CRT); Assigned to Arm(s): Patient Decision Aid for an ICD (primary prevention, non-CRT)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.
Brief Summary: To develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to bisphosphonates.


Options:
A: Arm Label: Absolute risk reduction information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Absolute risk reduction | Arm Label: Prolongation of life information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolongation of life | Intervention Type: BEHAVIORAL; Name: Absolute risk reduction; Assigned to Arm(s): Absolute risk reduction information | Intervention Type: BEHAVIORAL; Name: Prolongation of life; Assigned to Arm(s): Prolongation of life information
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training and coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication training and coaching; Assigned to Arm(s): Intervention
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoporosis Choice Decision Aid | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Osteoporosis Choice Decision Aid; Assigned to Arm(s): Arm 1
D: Arm Label: communication skills training; Type: EXPERIMENTAL; Interventions: Behavioral: patient training in shared decision making | Arm Label: cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive training | Intervention Type: BEHAVIORAL; Name: patient training in shared decision making; Assigned to Arm(s): communication skills training | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): cognitive training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Preoperative Treatment With Mifepristone on Uterine Fibroids and Breast Tissue
Brief Summary: Uterine fibroids are a benign but common condition among women in reproductive age. It is one of the most common reasons for hysterectomy since it often causes bleeding problems sometimes leading to anemia. Several alternative treatment regimens have been investigated that could replace surgery. The antiprogesterone, mifepristone, is one of the most promising drugs that have been tested. In addition to the inhibiting effect on the growth of uterine fibroids antiprogestins have been proposed to have an antiproliferative effect on breast tissue.

The purpose of the present study is to evaluate the effect of mifepristone on the volume of uterine fibroids. The study will also address the effect of mifepristone on the breast tissue


Options:
A: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mifegyne | Intervention Type: DRUG; Name: Mifegyne; Assigned to Arm(s): I | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin | Intervention Type: DRUG; Name: PGL4001, placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin; Assigned to Arm(s): B
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Preoperative Treatment With Mifepristone on Uterine Fibroids and Breast Tissue
Brief Summary: Uterine fibroids are a benign but common condition among women in reproductive age. It is one of the most common reasons for hysterectomy since it often causes bleeding problems sometimes leading to anemia. Several alternative treatment regimens have been investigated that could replace surgery. The antiprogesterone, mifepristone, is one of the most promising drugs that have been tested. In addition to the inhibiting effect on the growth of uterine fibroids antiprogestins have been proposed to have an antiproliferative effect on breast tissue.

The purpose of the present study is to evaluate the effect of mifepristone on the volume of uterine fibroids. The study will also address the effect of mifepristone on the breast tissue


Options:
A: Arm Label: Mifepristone 2.5 mg daily for three months; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of mifepristone 2.5 mg daily for three months | Arm Label: Mifepristone 5 mg daily for three months; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of mifepristone 5 mg daily for three months | Intervention Type: DRUG; Name: Oral administration of mifepristone 2.5 mg daily for three months; Assigned to Arm(s): Mifepristone 2.5 mg daily for three months | Intervention Type: DRUG; Name: Oral administration of mifepristone 5 mg daily for three months; Assigned to Arm(s): Mifepristone 5 mg daily for three months
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mifegyne | Intervention Type: DRUG; Name: Mifegyne; Assigned to Arm(s): I | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Immediate Versus Delayed Cord Clamping in the Preterm Neonate
Brief Summary: To determine the short and long term effects of placental transfusion at birth by milking and delayed cord clamping of the umbilical cord in neonates born between 24 weeks 0 days and 34 weeks 0 days weeks' gestation.


Options:
A: Arm Label: Umbilical Cord Milking; Type: EXPERIMENTAL; Interventions: Procedure: Umbilical Cord Milking | Arm Label: Immediate Cord Clamping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate Cord Clamping | Intervention Type: PROCEDURE; Name: Umbilical Cord Milking; Assigned to Arm(s): Umbilical Cord Milking | Intervention Type: PROCEDURE; Name: Immediate Cord Clamping; Assigned to Arm(s): Immediate Cord Clamping
B: Arm Label: Early umbilical cord clamping (control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed umbilical cord clamping; Type: EXPERIMENTAL; Interventions: Procedure: Delayed umbilical cord clamping | Intervention Type: PROCEDURE; Name: Delayed umbilical cord clamping; Assigned to Arm(s): Delayed umbilical cord clamping
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Delayed Cord Clamping | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate Cord Clamping | Intervention Type: PROCEDURE; Name: Delayed Cord Clamping; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Immediate Cord Clamping; Assigned to Arm(s): B
D: Arm Label: Immediate cord clamping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: delayed cord clamping | Arm Label: Delayed Cord Clamping; Type: EXPERIMENTAL; Interventions: Procedure: delayed cord clamping | Intervention Type: PROCEDURE; Name: delayed cord clamping; Assigned to Arm(s): Delayed Cord Clamping, Immediate cord clamping

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Brief Summary: The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial fibrillation (AF).


Options:
A: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Placebo (for warfarin), Drug: Avidin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Placebo (for idrabiotaparinux), Drug: Placebo (for avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for idrabiotaparinux); Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for warfarin); Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for avidin); Assigned to Arm(s): Warfarin
B: Arm Label: fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: fondaparinux | Intervention Type: DRUG; Name: fondaparinux; Assigned to Arm(s): fondaparinux
C: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin K antagonist (warfarin or acenocoumarol) tablets; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.
Brief Summary: During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.


Options:
A: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
C: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo
D: Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo

Answer: C